Ginkgo leaf oral liquid for strengthening health of heart and cerebral vessels as well as preparation method and application of ginkgo leaf oral liquid
By optimizing the extraction process of ginkgo leaves and wolfberry, Ginkgo leaf oral solution with high content of total flavonoids, ginkgo lactone, and wolfberry polysaccharides, the problem of poor improvement of cerebrovascular health in the existing technology center was solved, and the mild cognition was significantly improved Dysfunction and immune function are safe and efficient.
Patent Information
- Application Number
- CN202411075983.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-26
AI Technical Summary
The existing treatment methods for carotid atherosclerosis have irritating side effects on gastrointestinal function and have limited effect on improving cardiovascular and cerebrovascular health, especially in patients with mild cognitive dysfunction.
By optimizing the extraction process of ginkgo leaves and wolfberry, a Ginkgo leaf oral liquid was prepared, combining ginkgo leaf extract and wolfberry extract, ethanol reflux extraction and column chromatography technology were used to supercritical fluid extraction to form high content of total flavonoids and ginkgo. Ginkgo leaf oral liquid with lactone and wolfberry polysaccharide, add natural sweeteners to improve the efficacy and safety.
Ginkgo Leaf Oral Liquid can improve cardiovascular and cerebrovascular health, increase cerebral blood flow, improve memory, enhance immune function, and significantly improve the cure rate of mild cognitive dysfunction. It has small doses, high efficacy and high safety. Features.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of health care products, and specifically relates to a ginkgo leaf oral liquid for strengthening cardiovascular and cerebrovascular health, and a preparation method and application thereof. Background Art
[0002] Atherosclerotic diseases have a typical long preclinical stage, during which the function and morphology of the arterial wall deteriorate, which can eventually cause further cardiovascular and cerebrovascular lesions. At present, the treatment of carotid atherosclerosis requires improving lifestyle (such as quitting smoking, losing weight, and exercising), followed by controlling blood pressure, lowering blood lipids, and controlling diabetes. For patients with asymptomatic carotid atherosclerosis, low-dose rivaroxaban is more advantageous than low-dose aspirin in preventing cardiovascular disease. For patients with symptomatic carotid atherosclerosis, dual resistance (aspirin and clopidogrel) is required. However, Western medicine has side effects such as irritation to patients' gastrointestinal function. As people's health needs increase, research has turned its attention to safe and effective traditional Chinese medicine.
[0003] Carotid atherosclerosis is closely related to lipid metabolism disorders, and ginkgo preparations can lower blood lipids, reduce oxygen free radicals, inhibit the oxidation of low-density lipoprotein cholesterol, and inhibit platelet aggregation, so it is speculated that ginkgo oral liquid can improve atherosclerosis. Lycium barbarum is a traditional Chinese medicine and food with precious medicinal materials. It has multiple pharmacological effects such as enhancing immunity, anti-oxidation, anti-aging and synergistic anti-cancer. In particular, the flavonoids contained in wolfberry have the effects of improving cardiovascular and cerebrovascular diseases, regulating blood lipids, lowering blood pressure, and lowering blood sugar.
[0004] Therefore, the present invention further optimizes the extraction process on the basis of Chinese invention patent CN108671074 B to further concentrate the effective parts, and provides a ginkgo leaf oral liquid for strengthening cardiovascular and cerebrovascular health, and a preparation method and application thereof. Summary of the invention
[0005] The present invention aims at the problems existing in the prior art and provides a ginkgo leaf oral liquid for strengthening cardiovascular and cerebrovascular health and a preparation method and application thereof. The ginkgo leaf oral liquid provided by the present invention improves the overall condition of patients with mild cognitive dysfunction by increasing cerebral blood flow, resisting hypoxia, improving cardiovascular and cerebrovascular blood circulation, and improving brain energy metabolism, thereby removing oxygen free radicals, enhancing the body's immune function, facilitating the elimination of fatigue and improving memory, and has the characteristics of smaller dosage, higher efficacy, and better safety.
[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows: The first aspect of the present invention is to provide a ginkgo leaf oral liquid for strengthening cardiovascular and cerebrovascular health, wherein the ginkgo leaf oral liquid comprises ginkgo leaf extract and wolfberry extract, and the preparation steps of the ginkgo leaf extract are as follows: Y1: extracting ginkgo biloba leaves by ethanol reflux, recovering the solvent, and obtaining ginkgo biloba leaf ethanol extract; Y2: Ginkgo leaf alcohol extract was extracted by column chromatography to obtain Ginkgo leaf extract; The column chromatography extraction is that the alcohol extract of ginkgo leaves is passed through a D151 macroporous resin column, the elution solvent is dichloromethane-methanol, the elution gradient is a volume ratio of the two of 10:1-1:10, the eluate with a volume ratio of dichloromethane-methanol of 5:1-1:3 is collected, and the solvent is recovered to obtain the ginkgo leaf extract; The wolfberry extract is an extract obtained by supercritical fluid extraction of wolfberry; The mass ratio of the ginkgo leaf extract to the wolfberry extract is 3-7:1.
[0007] Preferably, in step Y1, the volume fraction of ethanol is 60%-95%, and the extraction is performed 2-3 times, each time for 1-3 hours.
[0008] Preferably, in step Y2, the flow rate of the eluent is 2-4 BV / h, and the volume of the eluent shared by the column chromatography is 10-20 BV.
[0009] Preferably, the mass percentage of the ginkgo leaf extract in the ginkgo leaf oral liquid is 0.05-1%.
[0010] Preferably, in the ginkgo leaf extract, the mass fraction of total flavonoids is 25-35%, the content of total terpenoid lactones is 5-10%, and the content of total ginkgolic acid is less than 1 ppm.
[0011] Preferably, the mass fraction of wolfberry polysaccharides in the wolfberry extract is 30-50%.
[0012] Preferably, the supercritical fluid extraction is supercritical carbon dioxide fluid extraction, the extraction temperature is 55-60°C, the extraction pressure is 5-10MPa, the separation pressure is 5-20MPa, the separation temperature is 50-60°C, and the extraction time is 1-3h.
[0013] Preferably, the supercritical carbon dioxide fluid extraction is divided into two steps, and the conditions of the extraction in step I are: separation I pressure is 10-20MPa, separation I temperature is 50-60°C, and extraction I time is 1-3h; the conditions of the extraction in step II are: separation II pressure is 5-10MPa, separation II temperature is 50-60°C, and extraction II time is 1-3h.
[0014] Preferably, the ginkgo leaf oral liquid also includes a natural sweetener.
[0015] Preferably, the added amount of the natural sweetener is 1-10% of the total mass of the ginkgo leaf extract and the wolfberry extract.
[0016] Further preferably, the natural sweetener is selected from at least one of steviol glycosides, mogrosides, glycyrrhizin, sweetening proteins and sugar alcohols.
[0017] More preferably, the sweet protein is selected from at least one of Thaumatin, Mabinlin, Pentadin, Curculin, Brazzein, Monellin and Miraculin.
[0018] More preferably, the sugar alcohol is at least one selected from erythritol, xylitol, sorbitol, maltitol, mannitol and lactitol.
[0019] The second aspect of the present invention is to provide a method for preparing the above-mentioned Ginkgo Biloba Oral Liquid, the preparation method comprising the following steps: K1: taking the ginkgo leaf extract and the wolfberry extract, or taking the ginkgo leaf extract, the wolfberry extract, and the natural sweetener, dissolving them in water to obtain a mixed aqueous solution; K2: Let stand at 4-8℃ for 12-24 hours, filter and obtain.
[0020] Preferably, in step K1, the mass ratio of the ginkgo leaf extract to the wolfberry extract is 3-7:1, and the mass percentage of the ginkgo leaf extract in the ginkgo leaf oral liquid is 0.05-1%.
[0021] The third aspect of the present invention relates to the use of the above-mentioned Ginkgo biloba oral liquid or the Ginkgo biloba oral liquid prepared according to the above-mentioned preparation method in strengthening cardiovascular and cerebrovascular health care products.
[0022] Compared with the prior art, the present invention has the following beneficial effects: the present invention further enriches the effective parts of ginkgo leaves that strengthen cardiovascular and cerebrovascular health through a chromatographic column, and extracts the relevant medicinal ingredients in wolfberry through supercritical fluid technology. The ginkgo leaf oral liquid composed of the ginkgo leaf extract and wolfberry extract obtained by the method of the present invention has the characteristics of high content of total flavonoids, ginkgolides, and wolfberry polysaccharides, and low content of ginkgolic acid; it can effectively improve the symptoms of hypoxia, improve memory, enhance immunity, and effectively improve the cure rate of mild cognitive dysfunction. The ginkgo leaf oral liquid has the characteristics of small dosage, high content of effective components, good effect, and higher safety, and is used in health care products that strengthen cardiovascular and cerebrovascular health. DETAILED DESCRIPTION
[0023] Example 1 A ginkgo leaf oral liquid is composed of a ginkgo leaf extract and a wolfberry extract, the mass ratio of the two being 4:1, and the preparation steps are as follows: (1) Preparation of Ginkgo Biloba Alcohol Extract: Weigh a certain amount of Ginkgo Biloba leaves, add 8 times the amount of 80% ethanol to extract twice, each time for 1 hour, recover the solvent, and obtain the Ginkgo Biloba Alcohol Extract; D151 macroporous resin column chromatography, the elution solvent is dichloromethane-methanol, the elution gradient is the volume ratio of the two is 10:1-1:10, the amount of eluent in each ratio is 1BV, the eluent flow rate is 2BV / h, collect the eluate with a volume ratio of dichloromethane-methanol of 5:1-1:3, recover the solvent, and obtain the Ginkgo Biloba Extract; (2) Preparation of wolfberry extract: dried wolfberry fruit medicinal material was taken, crushed by a grinder, and extracted by supercritical carbon dioxide fluid at an extraction temperature of 55°C, an extraction pressure of 10 MPa, a separation pressure of 20 MPa, a separation temperature of 50°C, and an extraction time of 2 h to obtain wolfberry extract; (3) Take 0.4 parts of the ginkgo leaf extract of step (1) and 0.1 parts of the wolfberry extract of step (2), dissolve them in water, dissolve them by ultrasonication, make the volume up to 100 parts with water, let stand at 4°C for 24 hours, and filter to obtain the product.
[0024] Example 2 A ginkgo leaf oral liquid is composed of a ginkgo leaf extract and a wolfberry extract, the mass ratio of the two being 4:1, and the preparation steps are as follows: (1) Preparation of Ginkgo Biloba Alcohol Extract: Weigh a certain amount of Ginkgo Biloba leaves, add 8 times the amount of 80% ethanol to extract twice, each time for 1 hour, recover the solvent, and obtain the Ginkgo Biloba Alcohol Extract; D151 macroporous resin column chromatography, the elution solvent is dichloromethane-methanol, the elution gradient is the volume ratio of the two is 10:1-1:10, the amount of eluent in each ratio is 1BV, the eluent flow rate is 2BV / h, collect the eluate with a volume ratio of dichloromethane-methanol of 5:1-1:1, recover the solvent, and obtain the Ginkgo Biloba Extract; (2) Preparation of wolfberry extract: dried wolfberry fruit medicinal material was taken, crushed by a grinder, and extracted by supercritical carbon dioxide fluid at an extraction temperature of 55°C, an extraction pressure of 10 MPa, a separation pressure of 20 MPa, a separation temperature of 50°C, and an extraction time of 2 h to obtain wolfberry extract; (3) Take 0.4 parts of the ginkgo leaf extract of step (1) and 0.1 parts of the wolfberry extract of step (2), dissolve them in water, dissolve them by ultrasonication, make the volume up to 100 parts with water, let stand at 4°C for 24 hours, and filter to obtain the product.
[0025] Example 3 A ginkgo leaf oral liquid is composed of a ginkgo leaf extract and a wolfberry extract, the mass ratio of the two being 4:1, and the preparation steps are as follows: (1) Preparation of Ginkgo Biloba Leaf Alcohol Extract: Weigh a certain amount of Ginkgo Biloba Leaf, add 8 times the amount of 80% ethanol to extract twice, each time for 1 hour, recover the solvent, and obtain the Ginkgo Biloba Leaf Alcohol Extract; D151 macroporous resin column chromatography, the elution solvent is dichloromethane-methanol, the elution gradient is the volume ratio of the two is 10:1-1:10, the amount of eluent in each ratio is 1BV, the eluent flow rate is 2BV / h, collect the eluate with a volume ratio of dichloromethane-methanol of 2:1-1:3, recover the solvent, and obtain the Ginkgo Biloba Leaf Extract; (2) Preparation of wolfberry extract: dried wolfberry fruit medicinal material was taken, crushed by a grinder, and extracted by supercritical carbon dioxide fluid at an extraction temperature of 55°C, an extraction pressure of 10 MPa, a separation pressure of 20 MPa, a separation temperature of 50°C, and an extraction time of 2 h to obtain wolfberry extract; (3) Take 0.4 parts of the ginkgo leaf extract of step (1) and 0.1 parts of the wolfberry extract of step (2), dissolve them in water, dissolve them by ultrasonication, make the volume up to 100 parts with water, let stand at 4°C for 24 hours, and filter to obtain the product.
[0026] Example 4 A ginkgo leaf oral liquid is composed of a ginkgo leaf extract and a wolfberry extract, the mass ratio of the two being 4:1, and the preparation steps are as follows: (1) Preparation of Ginkgo biloba extract: Weigh a certain amount of Ginkgo biloba, add 8 times the amount of 80% ethanol, extract twice, each time for 1 hour, recover the solvent, and obtain Ginkgo biloba alcohol extract; D151 macroporous resin column chromatography, the elution solvent is dichloromethane-methanol, the elution gradient is the volume ratio of the two is 10:1-1:10, the amount of eluent in each ratio is 1BV, the eluent flow rate is 2BV / h, collect the eluate with a volume ratio of dichloromethane-methanol of 5:1-1:3, recover the solvent, and obtain Ginkgo biloba extract; (2) Preparation of wolfberry extract: Dried wolfberry fruit was crushed by a pulverizer, and extracted with supercritical carbon dioxide fluid. The temperature of the extraction kettle was 60°C, the CO2 pressure was 10 MPa, the pressure of separation I was 20 MPa, the temperature of separation I was 60°C, and the extraction time was 1.5 h. The pressure of separation II was 10 MPa, the temperature of separation II was 60°C, and the extraction time was 1.5 h. The total extraction time was 3 h. The extraction temperature is 55°C, the extraction pressure is 10MPa, the separation pressure is 20MPa, the separation temperature is 50°C, and the extraction time is 2h to obtain a wolfberry extract; (3) Take 0.4 parts of the ginkgo leaf extract of step (1) and 0.1 parts of the wolfberry extract of step (2), dissolve them in water, dissolve them by ultrasonication, make the volume up to 100 parts with water, let stand at 4°C for 24 hours, and filter to obtain the product.
[0027] Comparative Example 1 The difference from Example 1 is that the purification method of the ginkgo leaf alcohol extract is different. In step (1), the ginkgo leaf alcohol extract is separated and purified using a D101 macroporous resin, first using 20% (volume fraction) ethanol as a decontamination solvent with an elution volume of 5 BV, and then using 60% (volume fraction) ethanol as an eluent with an elution volume of 4 BV to obtain the ginkgo leaf extract. The remaining steps are the same as in Example 1.
[0028] Comparative Example 2 The difference from Example 1 is that the preparation method of the wolfberry extract is different, specifically: the wolfberry is boiled in water at 70° C. for 2 times, each time for 1 hour, filtered, and the filtrate is concentrated and dried under reduced pressure at 60° C. to obtain the wolfberry extract. The remaining steps are as in Example 1.
[0029] Comparative Example 3 According to Example 1 in Chinese invention patent CN108671074 B, a Ginkgo biloba and wolfberry compound oral liquid is prepared, comprising the following steps: (1) Preparation of water-soluble ginkgo leaf extract Take 2000 grams of fat-soluble ginkgo leaf extract, add 15 liters (1500 ml) of 22% ethanol at 50°C, stir thoroughly to dissolve it, cool it and place it overnight, filter to obtain filtrate A, and dry the filter residue. Place filtrate A in a decompression tank to reduce pressure, recover ethanol until there is no alcohol taste, and continuously add 10 liters (10000 ml) of 52°C hot water to filtrate A during the recovery of ethanol, so that the weight content of solids accounts for 7% of the volume fraction of the solvent, place it at room temperature overnight, and filter to obtain filtrate B, i.e., water-soluble ginkgo leaf extract. Samples are taken to detect the total flavonoid content, the content of linalool and the content of ginkgolic acid. The detection methods are all in accordance with the provisions of the Chinese Pharmacopoeia 2015 edition of ginkgo leaf extract, high performance liquid chromatography (General Rule 0512). Results: The total flavonoid content is 25.5%, the linalool content is 7%, and the ginkgolic acid content is less than 5ppm.
[0030] (2) Preparation of Lycium barbarum Extract The wolfberry was boiled in water at 70°C for 2 times, each time for 1 hour, filtered, and the filtrate was concentrated under reduced pressure at 60°C to obtain the wolfberry extract. The ratio of the obtained wolfberry extract to the wolfberry used to prepare the wolfberry extract was 1 mL:1 g.
[0031] (3) Preparation of Ginkgo Leaf and Wolfberry Aqueous Solution Take water-soluble ginkgo leaf extract and wolfberry extract, dissolve them in water respectively and then mix them to obtain a ginkgo leaf and wolfberry aqueous solution, the mass percentage of the water-soluble ginkgo leaf extract in the ginkgo leaf and wolfberry aqueous solution is 0.4%, and the mass percentage of the wolfberry extract in the ginkgo leaf and wolfberry aqueous solution is 0.1%.
[0032] (4) preparing the ginkgo leaf and wolfberry compound oral liquid The ginkgo leaf and wolfberry aqueous solution was allowed to settle at 12°C for 72 hours, and then filtered with a titanium rod to obtain the ginkgo leaf and wolfberry compound oral liquid.
[0033] Experiment 1 Determination of the content of total flavonoids, ginkgolides, Lycium barbarum polysaccharides and ginkgo acid in ginkgo leaf extracts The detection methods of total flavonoids and ginkgolide in the preparations are in accordance with the provisions of the Chinese Pharmacopoeia 2020 edition under the Ginkgo Leaf Extract, HPLC (General Rule 0512); the detection method of Lycium barbarum polysaccharides is determined according to the determination method of Lycium barbarum polysaccharides in Lycium barbarum in the Chinese Pharmacopoeia 2020 edition, and the ginkgolic acid (ppm) in Ginkgo Leaf Extract is determined according to the Chinese Pharmacopoeia 2020 edition (General Rule 2302). The specific results are shown in the following table: Table 1: Determination results of related substances preparation Total flavonoids (mg / 100mL) Ginkgolide (mg / 100mL) Lycium barbarum polysaccharide (mg / 100mL) Ginkgo biloba extract ginkgolic acid (ppm) Example 1 123.94 35.42 72.25 <1 Example 2 117.65 31.28 72.69 <1 Example 3 108.42 28.14 72.43 <1 Example 4 122.86 35.77 85.76 <1 Comparative Example 1 43.55 5.84 71.98 2.45 Comparative Example 2 120.11 36.15 33.69 <1 Comparative Example 3 80.34 2.57 34.55 4.32 From the experimental results in Table 1, it can be seen that the contents of total flavonoids and ginkgolide in the preparations of Examples 1-4 are much higher than those in Comparative Examples 1 and 3, and the contents of Lycium barbarum polysaccharides in Examples 1-4 are much higher than those in Comparative Examples 2 and 3, and supercritical fluid step-by-step extraction is more conducive to the extraction of Lycium barbarum polysaccharides. At the same time, the content of ginkgolic acid in the ginkgo leaf extract of the present invention is significantly reduced, and the content of ginkgolic acid in the ginkgo leaf extract of each embodiment is less than 1ppm. Therefore, the ginkgo leaf oral liquid of the present invention has the characteristics of high content of total flavonoids, ginkgolides, and Lycium barbarum polysaccharides and low content of ginkgolic acid.
[0034] Experimental Example 2 Hypoxia Sealed Test 90 mice were randomly divided into 9 groups, 10 mice in each group, half of them were male and half were female. The blank group was gavaged with normal saline (50 mL / kg), the positive control drug nimodipine (dosage was 120 mg / kg), and the corresponding drugs (dosage was 50 mL / kg) were gavaged in Example 1-4 and Comparative Example 1-3 groups. The drugs were administered once a day for 30 consecutive days. One hour after the last administration, the mice in each dosage group were placed in a 250 ml ground-mouth bottle containing 5 g of soda lime (1 per bottle), the bottle mouth was sealed with vaseline, and the cover was tightly covered to prevent air leakage. The time was immediately counted, and respiratory arrest was used as an indicator to observe the time when the mice died due to hypoxia. The differences between the groups were compared using the T test, and the results are shown in Table 2.
[0035] Table 2: Effects on the hypoxia tolerance time at normal pressure in mice Group Survival time (min) Increase rate (%) Significance Blank Group 18.24±1.41 - Positive control group 23.57±1.53 28.30 *** Example 1 23.49±1.48 28.75 *** Example 2 22.94±1.36 25.92 ** Example 3 23.10±1.39 26.13 ** Example 4 23.97±1.65 29.14 *** Comparative Example 1 21.94±1.44 22.16 * Comparative Example 2 22.68±1.38 23.14 * Comparative Example 3 22.49±1.38 22.70 * Note: Compared with the blank group, *P<0.05, **P<0.01, ***P<0.001.
[0036] After oral gavage administration for 30 consecutive days, it can be seen that the animals grow well, the hypoxia tolerance test results are positive, and the survival time of mice in a hypoxic environment can be significantly prolonged. The survival time in a hypoxic environment is close to or better than the positive control drug nimodipine that can effectively improve hypoxia. The hypoxia tolerance test results of Examples 1-4 of the present invention are significantly better than the effects of Comparative Examples 1-3. The ginkgo leaf oral liquid disclosed by the present invention can effectively improve the symptoms of hypoxia.
[0037] Experimental Example 3: Jumping Platform Experiment 100 mice were randomly divided into 10 groups, 10 mice in each group, half of which were male and half were female, and were gavaged respectively. The blank group and the model group were gavaged with normal saline (50mL / kg), and the positive control drug nimodipine (dosage was 120mg / kg). The corresponding drugs (dosage was 50mL / kg) were gavaged in the Example 1-4 and the Comparative Example 1-3 groups, and the drugs were administered once a day for 10 consecutive days. The mice were trained after three days of administration. Each mouse was administered with a jumping platform for 5 minutes one hour after administration. The time when the mouse jumped off the platform for the first time was recorded as the incubation period 1 hour after the last administration, and the number of times the mouse jumped off the jumping platform within 5 minutes was recorded. If the mouse did not jump off the platform within 5min, the incubation period was calculated as 300s. In the first ten minutes of the determination, all mice except the blank group were intraperitoneally injected with scopolamine (1mg / kg), and the differences between the groups were compared by T test. The results are shown in Table 3.
[0038] Table 3: Latency and number of errors in the mouse jumping test (X±SD) Group Incubation period (s) Number of errors Blank Group 195.50±13.63 2.08±1.62 Model Group <![CDATA[139.25±25.32 ### ]]> <![CDATA[5.42±4.15 ## ]]> Positive control group 188.46±16.74*** 1.47±1.22*** Example 1 189.62±15.18*** 1.25±1.63*** Example 2 166.30±20.26** 1.67±1.68** Example 3 177.41±17.49*** 1.89±1.54** Example 4 178.76±18.37*** 1.33±1.56*** Comparative Example 1 149.23±17.41 3.94±2.79* Comparative Example 2 158.46±18.45* 3.12±2.34* Comparative Example 3 153.47±19.23* 3.56±1.92* Note: Compared with the blank group, the model group # P<0.05, ## P<0.01, ### P<0.001; compared with the model group, *P<0.05, **P<0.01, ***P<0.001.
[0039] Compared with the blank group, the model group mice significantly shortened the platform jumping latency (P<0.001); compared with the model group, Examples 1-4 can significantly prolong the platform jumping latency (P<0.01 or P<0.001), and the effect is significantly better than that of the comparative example 1-3 group. Compared with the blank group, the number of errors of the model group mice increased significantly (P<0.01); compared with the model group, the examples 1-4 groups of the present invention can significantly reduce the number of errors (P<0.01 or P<0.001), and the effect is significantly better than that of the comparative example 1-3 group. Therefore, it can be determined that the ginkgo leaf oral liquid of the present invention has the effect of significantly improving memory.
[0040] Experimental Example 4 Effect on Immunity This section adopts the evaluation method recorded in "I. Test method for helping to enhance immunity" in the "Health Food Function Test and Evaluation Method (2022 Edition)" to carry out functional testing on whether the oral liquid of the present invention can help enhance immunity.
[0041] 80 male Kunming mice aged 6-8 weeks and weighing between 18-22g were selected and randomly divided into 8 groups according to their weight, with 10 mice in each group; they were blank group, Example 1-4 group, and Comparative Example 1-3 group. Different groups were fed with basic feed, the blank group was gavaged with physiological saline (50mL / kg), and the Example 1-4 group and Comparative Example 1-3 group were gavaged with corresponding oral solution (50mL / kg). The experimental period was 4 weeks, and the following studies were conducted respectively: ①Measurement of mouse body weight changes ② Determination of the organ-body ratio of mice: the ratio of the weight of the mouse immune organs thymus and spleen to body weight ③ Cellular immune function assay: mouse spleen lymphocyte transformation experiment, delayed-type hypersensitivity reaction experiment The mouse spleen lymphocyte transformation experiment uses the MTT method to determine the lymphocyte proliferation ability. The stronger the lymphocyte proliferation ability, the stronger the immunity. Mouse delayed allergy test (plantar thickness increase method): immunize animals on the 4th day before the end of the experiment, inject 0.2mL of 2% (v / v) sheep red blood cells intraperitoneally to sensitize the animals, measure the thickness of the left hind paw plantar part 5 days later, then inject 20% (v / v) sheep red blood cells (20μL / mouse) subcutaneously there, measure the thickness of the left hind paw plantar part three times 24h after injection, and obtain the average value; ④Humoral immune function test: antibody-producing cell test, serum hemolysin test Determination of the number of antibody-producing cells: that is, determination of the number of hemolytic plaques. The larger the number of hemolytic plaques, the stronger the humoral immune function of the mouse; Serum hemolysin determination: that is, the anti-volume number. The larger the anti-volume number, the stronger the humoral immunity; ⑤NK cell activity assay The present invention adopts lactate dehydrogenase (LDH) method to detect NK cell activity, and the specific method is as follows: Prepare spleen cell suspension (effector cells) according to the method described in "I. Test Methods for Helping to Enhance Immunity" in the "Health Food Function Test and Evaluation Methods (2022 Edition)".
[0042] The concentration in the reaction well was 4×10 5100 μL of YAC-1 target cells and effector cells (effector to target ratio of 50:1) at a concentration of 1 cell / mL were added to a U-shaped 96-well culture plate; 100 μL of target cells and culture medium were added to the wells for natural release of target cells, and 100 μL of target cells and 1% NP-40 were added to the wells for maximum release of target cells; three replicate wells were set for each of the above items, and the cells were cultured in a 37°C, 5% CO2 incubator for 4 h, and then the 96-well culture plate was centrifuged at 1500 rpm for 5 min, 100 μL of supernatant was aspirated from each well and placed in a flat-bottomed 96-well culture plate, and 100 μL of LDH matrix solution was added at the same time. The reaction was allowed to proceed for 3 min, and 30 μL of 1 mol / L HCl was added to each well. The optical density was measured at 492 nm using an enzyme-linked immunosorbent assay.
[0043] NK cell activity (%) = (response well OD - natural release well OD) / (maximum release well OD - natural release well OD) × 100%.
[0044] The statistical results of the body weight, organ-to-body ratio, immune function, NK cell activity and other indicators of Kunming mice in different groups are shown in Table 4 below.
[0045] Table 4: Effects on immunity of mice
[0046] Note: Compared with the blank group, *P<0.05, **P<0.01, ***P<0.001 It can be seen from the test results that there was no significant difference in the mean body weight of each group of mice in this experiment; compared with the blank group, the groups 1-4 of Examples of the present invention showed significant differences in indicators such as thymus / body weight, spleen / body weight, toe thickening, splenic lymphocyte transformation optical density difference, hemolytic plaque number, anti-volume number and NK cell activity, that is, the results in the three aspects of cellular immune function, humoral immune function and NK cell activity were all positive, and the effect was significantly better than that of the comparative example 1-3 groups. Therefore, according to the functional test method and result judgment that helps to enhance immunity in the "Health Food Function Test and Evaluation Method (2022 Edition)", it is judged that the ginkgo leaf oral liquid of the present invention has the effect of enhancing immunity.
[0047] Experimental Example 5: Improvement of Mild Cognitive Impairment Patients diagnosed with mild cognitive impairment were scored using the MMSE scoring method, and the conditions of the patients before and after taking the medication were compared. The specific results are shown in Table 5.
[0048] Table 5: Improvement of mild cognitive impairment Group Total number of people with mild cognitive impairment before taking the drug Total number of people with mild cognitive impairment after taking Example 1 25 4 Example 2 24 5 Example 3 25 4 Example 4 23 3 Comparative Example 1 25 12 Comparative Example 2 25 10 Comparative Example 3 24 15 According to the data in the table, the effective rate of Example 1 is 84%, the effective rate of Example 2 is 79.12%, the effective rate of Example 3 is 84%, the effective rate of Example 4 is 86.96%, the effective rate of Comparative Example 1 is 52%, the effective rate of Comparative Example 2 is 60%, and the effective rate of Comparative Example 3 is 37.5%. The present invention has a significant effect and can effectively improve the cure rate of mild cognitive impairment.
[0049] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A ginkgo leaf oral solution for strengthening cardiovascular and cerebrovascular health. It is characterized in that The ginkgo leaf oral liquid comprises ginkgo leaf extract and wolfberry extract, and the preparation steps of the ginkgo leaf extract are as follows: Y1: extracting ginkgo biloba leaves by ethanol reflux, recovering the solvent, and obtaining ginkgo biloba leaf ethanol extract; Y2: Ginkgo leaf alcohol extract was extracted by column chromatography to obtain Ginkgo leaf extract; The column chromatography extraction is that the alcohol extract of ginkgo leaves is passed through a D151 macroporous resin column, the elution solvent is dichloromethane-methanol, the elution gradient is a volume ratio of the two of 10:1-1:10, the eluate with a volume ratio of dichloromethane-methanol of 5:1-1:3 is collected, and the solvent is recovered to obtain the ginkgo leaf extract; The wolfberry extract is an extract obtained by supercritical fluid extraction of wolfberry; The mass ratio of the ginkgo leaf extract to the wolfberry extract is 3-7:
1.
2. The ginkgo leaf oral solution as claimed in claim 1, It is characterized in that In step Y1, the volume fraction of ethanol is 60%-95%, and the extraction is performed 2-3 times, with the volume of ethanol used for each extraction being 6-10 times the mass of the ginkgo leaves, and each extraction is performed for 1-3 hours.
3. The ginkgo leaf oral solution as claimed in claim 1, It is characterized in that In step Y2, the flow rate of the eluent is 2-4 BV / h, and the volume of the eluent shared by the column chromatography is 10-20 BV.
4. The ginkgo leaf oral liquid as claimed in claim 1, It is characterized in that The mass percentage of the ginkgo leaf extract in the ginkgo leaf oral liquid is 0.05-1%.
5. The ginkgo leaf oral liquid as claimed in claim 1, It is characterized in that In the ginkgo leaf extract, the mass fraction of total flavonoids is 25-35%, the content of total terpenoid lactones is 5-10%, and the content of total ginkgolic acid is less than 1 ppm; in the wolfberry extract, the mass fraction of wolfberry polysaccharides is 30-50%.
6. The ginkgo leaf oral liquid as claimed in claim 1, It is characterized in that The supercritical fluid extraction is supercritical carbon dioxide fluid extraction, the extraction temperature is 55-60° C., the extraction pressure is 5-10 MPa, the separation pressure is 5-20 MPa, the separation temperature is 50-60° C., and the extraction time is 1-3 h.
7. The ginkgo leaf oral liquid as claimed in claim 1, It is characterized in that The supercritical carbon dioxide fluid extraction is divided into two steps. The conditions of the extraction in step I are: the separation I pressure is 10-20MPa, the separation I temperature is 50-60°C, and the extraction I time is 1-3h; the conditions of the extraction in step II are: the separation II pressure is 5-10MPa, the separation II temperature is 50-60°C, and the extraction II time is 1-3h.
8. The ginkgo leaf oral liquid as claimed in claim 1, It is characterized in that The ginkgo leaf oral solution also includes a natural sweetener.
9. A method for preparing the ginkgo leaf oral liquid according to any one of claims 1 to 8, It is characterized in that The preparation method comprises the following steps: K1: taking the ginkgo leaf extract and the wolfberry extract, or taking the ginkgo leaf extract, the wolfberry extract, and the natural sweetener, dissolving them in water to obtain a mixed aqueous solution; K2: Let stand at 4-8℃ for 120-240 hours, filter and obtain.
10. Use of the ginkgo leaf oral liquid according to any one of claims 1 to 8 or the ginkgo leaf oral liquid prepared by the preparation method according to claim 9 in strengthening cardiovascular and cerebrovascular health care products.
Citation Information
Patent Citations
Ginkgo biloba and wolfberry compound oral liquid for the prevention and / or treatment of cardiovascular and cerebrovascular diseases and its preparation method
CN108671074B
Method for extracting lycium barbarum extract by supercritical CO2
CN102988605A
Extraction method for FructusLycii active ingredient
CN104623095A
New preparing method of high purity shiny-leaved yellowhorn total saponins extractive and application thereof
CN106421077A
Folium ginkgo and fructus lycii compound oral liquid for preventing and / or treating cardiovascular and cerebrovascular diseases and preparation method thereof
CN108671074A
